The HPV, p53, and p16 tumor marker analysis revealed p16(+) in 86% of cases, which was a significantly higher frequency (p = 0.03) compared to that of the p53(+) identified in 70% of the cases. This evidence concerns the gene CDKN2A and neoplasm.